Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Financings

Bausch Health Announces Final Results and Expiration of Exchange Offers

By The Northwire Desk — AI Analysis Dec 23, 2025 · 17:35 BHC · 10.04 BAUSCH HEALTH COMPANIES INC.
BHC · Price

Executive Summary

  • Bausch Health announced the final results and expiration of its exchange offers to swap existing 4.875% and 11.00% senior secured notes due 2028 for new 10.00% senior secured notes due 2032, with up to $1.6 billion of new notes to be issued.
  • Holders tendered $2.7 billion of existing notes; approximately $1.6 billion principal amount of the new notes will be issued upon settlement expected on December 26, 2025.
  • The exchange provides cash adjustments for accrued interest differences and is being overseen by legal counsel Sullivan & Cromwell LLP, Norton Rose Fulbright Canada LLP, and financial advisor Evercore Inc.

Key Details

  • Existing Notes Tendered: $2.7 billion aggregate principal amount of 4.875% and 11.00% senior secured notes due 2028.
  • Accepted for Exchange:
  • 11.00% Notes – $885,806,000 accepted; total consideration $1,020 per $1,000 of existing principal.
  • 4.875% Notes – $797,431,000 accepted; total consideration $873.84 per $1,000 of existing principal (adjusted for net interest payment).
  • New Notes to be Issued: Approximately $1.6 billion principal amount of 10.00% senior secured notes due 2032.
  • Settlement Date: Expected December 26, 2025.
  • Cash Component: Eligible holders will receive cash equal to the difference between accrued interest on existing notes and accrued/unpaid interest on the new notes up to the settlement date.
  • Legal & Financial Advisors: Sullivan & Cromwell LLP; Norton Rose Fulbright Canada LLP (legal); Evercore Inc. (financial advisor).
  • Regulatory Disclaimers: New notes not registered under U.S. securities laws; offering in Canada will rely on exemption from prospectus requirements.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

Jun 09, 2026 · 08:00

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

Regulatory May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other Feb 23, 2026 · 17:59

Bausch Health launches Clear + Brilliant in Canada

Regulatory Feb 23, 2026 · 08:00

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

Production / Operations